Strategies and Barriers in mUC Maintenance Therapy

Video

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Recent Videos
4 experts in this video
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
4 experts in this video
4 experts in this video
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content
Most patients with BCG-unresponsive NMIBC treated with detalimogene voraplasmid did not experience TRAEs, with only 1.6% experiencing dose interruptions.

Detalimogene Exhibits Improved Response Rate in BCG-Unresponsive NMIBC

Roman Fabbricatore
November 12th 2025
Article

Most patients with BCG-unresponsive NMIBC treated with detalimogene voraplasmid did not experience TRAEs, and only 1.6% experienced dose interruptions.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Site Logo

BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer

Roman Fabbricatore
November 1st 2025
Article

Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Regarding safety, the toxicity profile of the pembrolizumab plus belzutifan combination was consistent with what has been observed in previously reported trials.

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Tim Cortese
October 29th 2025
Article

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.

The developers will present these data at an upcoming medical meeting and plan to begin discussions with regulatory authorities.

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Tim Cortese
October 28th 2025
Article

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.